Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23349335 | 0.98 | NPC1 (0.33) | NPC1RAB9AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL24221667 | 0.98 | NPC1 (0.33) | NPC1RAB9AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21576242 | 0.94 | HPGD (0.32) | HTTSMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL14704043 | 0.75 | DRD3 (0.39) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL13394781 | 0.73 | DRD3 (0.38) | HTTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL20345516 | 0.72 | GAA (0.35) | HTTSMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL12044892 | 0.71 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12024887 | 0.71 | KDM4E (0.33) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL25091827 | 0.69 | COMT (0.35) | ALDH1A1 | |
| SCHEMBL21576049 | 0.69 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022043465-A1 | INHIBITORS OF NO PRODUCTION | MAX DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-03-03 | — | — | WO | disclosed |
| US-9284350-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | NPC1 818/4885RAB9A 1937/4885HTT 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.